A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
Completed
Ovid Therapeutics Inc.
Phase 2
The purpose of this study is to investigate the effect of soticlestat on the frequency of
motor seizures for participants with Dup15q or CDD during the Maintenance Period.
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
Completed
Takeda
Phase 2
The purpose of this study is to investigate the effect of soticlestat on the frequency of
motor seizures for participants with Dup15q or CDD during the Maintenance Period.
Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS)
Completed
Millennium Pharmaceuticals, Inc.
Phase 2
The purpose of this study is to investigate the effect of soticlestat (TAK-935) on calculated
24-hour average pain intensity by the numeric pain scale (NPS).
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
Recruiting
Takeda
Phase 3
The aims of the study are:
- to learn if soticlestat, when given as add-on therapy, reduces the number of major motor
drop seizures in children, teenagers, and adults with Lennox-Gastaut Syndrome.
- to assess the safety profile of soticlestat when given in combination with other
therapies.
Participants will receive their standard anti-seizure therapy, plus either tablets of
soticlestat or placebo. A placebo looks just like soticlestat but will not have any medicine
in it. Participants will take soticlestat or placebo for 16 weeks, followed by a gradual dose
reduction for 1 week. Then, participants will be followed up for 2 weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
